S&P 500   4,563.49 (-0.68%)
DOW   36,185.93 (-0.16%)
QQQ   385.14 (-1.23%)
AAPL   188.62 (-1.37%)
MSFT   368.34 (-1.65%)
META   316.57 (-2.54%)
GOOGL   128.33 (-2.68%)
AMZN   144.61 (-1.65%)
TSLA   237.06 (-0.74%)
NVDA   451.77 (-3.40%)
NIO   7.31 (+2.24%)
BABA   73.14 (-1.15%)
AMD   118.35 (-2.50%)
T   16.62 (-0.84%)
F   10.69 (+1.04%)
MU   73.94 (-2.62%)
CGC   0.72 (+17.01%)
GE   121.57 (-0.76%)
DIS   92.23 (-0.38%)
AMC   7.29 (+6.27%)
PFE   29.45 (+1.87%)
PYPL   59.86 (+0.35%)
XOM   102.66 (-0.32%)
S&P 500   4,563.49 (-0.68%)
DOW   36,185.93 (-0.16%)
QQQ   385.14 (-1.23%)
AAPL   188.62 (-1.37%)
MSFT   368.34 (-1.65%)
META   316.57 (-2.54%)
GOOGL   128.33 (-2.68%)
AMZN   144.61 (-1.65%)
TSLA   237.06 (-0.74%)
NVDA   451.77 (-3.40%)
NIO   7.31 (+2.24%)
BABA   73.14 (-1.15%)
AMD   118.35 (-2.50%)
T   16.62 (-0.84%)
F   10.69 (+1.04%)
MU   73.94 (-2.62%)
CGC   0.72 (+17.01%)
GE   121.57 (-0.76%)
DIS   92.23 (-0.38%)
AMC   7.29 (+6.27%)
PFE   29.45 (+1.87%)
PYPL   59.86 (+0.35%)
XOM   102.66 (-0.32%)
S&P 500   4,563.49 (-0.68%)
DOW   36,185.93 (-0.16%)
QQQ   385.14 (-1.23%)
AAPL   188.62 (-1.37%)
MSFT   368.34 (-1.65%)
META   316.57 (-2.54%)
GOOGL   128.33 (-2.68%)
AMZN   144.61 (-1.65%)
TSLA   237.06 (-0.74%)
NVDA   451.77 (-3.40%)
NIO   7.31 (+2.24%)
BABA   73.14 (-1.15%)
AMD   118.35 (-2.50%)
T   16.62 (-0.84%)
F   10.69 (+1.04%)
MU   73.94 (-2.62%)
CGC   0.72 (+17.01%)
GE   121.57 (-0.76%)
DIS   92.23 (-0.38%)
AMC   7.29 (+6.27%)
PFE   29.45 (+1.87%)
PYPL   59.86 (+0.35%)
XOM   102.66 (-0.32%)
S&P 500   4,563.49 (-0.68%)
DOW   36,185.93 (-0.16%)
QQQ   385.14 (-1.23%)
AAPL   188.62 (-1.37%)
MSFT   368.34 (-1.65%)
META   316.57 (-2.54%)
GOOGL   128.33 (-2.68%)
AMZN   144.61 (-1.65%)
TSLA   237.06 (-0.74%)
NVDA   451.77 (-3.40%)
NIO   7.31 (+2.24%)
BABA   73.14 (-1.15%)
AMD   118.35 (-2.50%)
T   16.62 (-0.84%)
F   10.69 (+1.04%)
MU   73.94 (-2.62%)
CGC   0.72 (+17.01%)
GE   121.57 (-0.76%)
DIS   92.23 (-0.38%)
AMC   7.29 (+6.27%)
PFE   29.45 (+1.87%)
PYPL   59.86 (+0.35%)
XOM   102.66 (-0.32%)

Ardelyx (ARDX) News Today

$4.89
+0.13 (+2.73%)
(As of 02:04 PM ET)
Compare
Today's Range
$4.62
▼
$4.91
50-Day Range
$3.29
▼
$4.76
52-Week Range
$1.70
▼
$5.13
Volume
2.12 million shs
Average Volume
6.16 million shs
Market Capitalization
$1.13 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.10
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability
SourceHeadline
MarketBeat logoArdelyx's (ARDX) Outperform Rating Reaffirmed at Wedbush
americanbankingnews.com - December 3 at 2:18 AM
MarketBeat logoArdelyx, Inc. (NASDAQ:ARDX) Receives Average Recommendation of "Buy" from Brokerages
americanbankingnews.com - December 3 at 1:24 AM
markets.businessinsider.com logoThe Latest Analyst Ratings for Ardelyx
markets.businessinsider.com - December 1 at 12:42 PM
benzinga.com logoThinking about buying stock in Perfect Corp, UP Fintech, Theseus Pharmaceuticals, Reliance Sekuritas Indonesia, or Ardelyx?
benzinga.com - November 27 at 10:35 AM
msn.com logoArdelyx (ARDX) Price Target Increased by 6.30% to 9.84
msn.com - November 27 at 10:35 AM
finance.yahoo.com logoArdelyx to Participate at the Piper Sandler 35th Annual Healthcare Conference
finance.yahoo.com - November 21 at 8:22 AM
finanznachrichten.de logoArdelyx, Inc.: XPHOZAH (tenapanor) Granted Orphan Drug Designation by U.S. FDA for the Treatment of Pediatric Hyperphosphatemia
finanznachrichten.de - November 16 at 8:36 AM
msn.com logoArdelyx gets FDA orphan drug designation for pediatric Xphozah
msn.com - November 15 at 7:38 PM
finance.yahoo.com logoXPHOZAH® (tenapanor) Granted Orphan Drug Designation by U.S. FDA for the Treatment of Pediatric Hyperphosphatemia
finance.yahoo.com - November 15 at 7:38 PM
finance.yahoo.com logoArdelyx (NASDAQ:ARDX) shareholders have earned a 226% return over the last year
finance.yahoo.com - November 15 at 2:38 PM
finance.yahoo.com logoArdelyx Announces Departure of Board Member
finance.yahoo.com - November 13 at 7:22 PM
finance.yahoo.com logoArdelyx to Participate at the Jefferies London Healthcare Conference
finance.yahoo.com - November 10 at 12:17 PM
finance.yahoo.com logoArdelyx Announces XPHOZAH® (tenapanor) Now Available in the United States
finance.yahoo.com - November 6 at 10:15 AM
finance.yahoo.com logoArdelyx Shares Positive Data from Studies of XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor, at ASN Kidney Week 2023
finance.yahoo.com - November 3 at 8:31 AM
markets.businessinsider.com logoPiper Sandler Keeps Their Buy Rating on Ardelyx (ARDX)
markets.businessinsider.com - November 1 at 11:05 PM
finance.yahoo.com logoArdelyx, Inc. (NASDAQ:ARDX) Q3 2023 Earnings Call Transcript
finance.yahoo.com - November 1 at 1:04 PM
msn.com logoArdelyx (ARDX) Price Target Increased by 6.72% to 9.25
msn.com - October 31 at 8:47 PM
msn.com logoArdelyx gains as Ibsrela drives strong Q3 beat
msn.com - October 31 at 3:46 PM
finance.yahoo.com logoArdelyx (ARDX) Q3 Earnings and Revenues Top Estimates
finance.yahoo.com - October 31 at 3:46 PM
finanznachrichten.de logoArdelyx, Inc.: Ardelyx Reports Third Quarter 2023 Financial Results and Updates 2023 U.S. IBSRELA Net Sales Revenue Guidance
finanznachrichten.de - October 31 at 9:40 AM
finance.yahoo.com logoArdelyx Reports Third Quarter 2023 Financial Results and Updates 2023 U.S. IBSRELA® Net Sales Revenue Guidance
finance.yahoo.com - October 31 at 9:40 AM
finance.yahoo.com logoThis Ardelyx Insider Increased Their Holding By 95% Last Year
finance.yahoo.com - October 30 at 7:09 AM
stockhouse.com logoArdelyx Shares Positive Data on Symptom Response During Treatment With IBSRELA® (tenapanor) for IBS-C and hosts IBS-C Product Theater at ACG 2023
stockhouse.com - October 23 at 12:28 PM
finance.yahoo.com logoArdelyx Shares Positive Data on Symptom Response During Treatment With IBSRELA® (tenapanor) for IBS-C and hosts IBS-C Product Theater at ACG 2023
finance.yahoo.com - October 23 at 12:28 PM
finance.yahoo.com logoArdelyx (ARDX) Up on FDA Nod to Xphozah for Hyperphosphatemia
finance.yahoo.com - October 19 at 3:44 PM
msn.com logoArdelyx granted FDA nod for kidney disease therapy
msn.com - October 19 at 10:44 AM
benzinga.com logoCrude Oil Rises Sharply; Ardelyx Shares Spike Higher
benzinga.com - October 18 at 6:06 PM
theglobeandmail.com logoBiotech Finds Mid-Week Success Following FDA Announcement
theglobeandmail.com - October 18 at 6:06 PM
bizjournals.com logoArdelyx had sales team, launch plan ready to go before dialysis drug approval
bizjournals.com - October 18 at 6:06 PM
finance.yahoo.com logoArdelyx to Report Third Quarter 2023 Financial Results on October 31, 2023
finance.yahoo.com - October 18 at 6:06 PM
finance.yahoo.com logoWhy Ardelyx Stock Popped Today
finance.yahoo.com - October 18 at 6:05 PM
markets.businessinsider.com logoAnalysts Are Bullish on These Healthcare Stocks: Align Tech (ALGN), Ardelyx (ARDX)
markets.businessinsider.com - October 18 at 1:05 PM
markets.businessinsider.com logoAfter Initial Rejection, FDA Approves Ardelyx's Kidney Disease-Related Drug
markets.businessinsider.com - October 18 at 1:05 PM
investorplace.com logoFDA Sends ARDX Stock Soaring After Approving Ardelyx’s Kidney Disease Drug
investorplace.com - October 18 at 12:04 PM
finanznachrichten.de logoArdelyx, Inc.: Ardelyx to Present Data Updates for XPHOZAH (tenapanor) for Hyperphosphatemia at Kidney Week 2023 November 1-5 in Philadelphia, PA
finanznachrichten.de - October 18 at 8:05 AM
seekingalpha.com logoArdelyx: XPHOZAH Is No Niche Product
seekingalpha.com - October 18 at 2:39 AM
benzinga.com logoFDA Approves XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor
benzinga.com - October 17 at 8:21 PM
reuters.com logoUS FDA approves Ardelyx's kidney disease-related drug
reuters.com - October 17 at 8:21 PM
bizjournals.com logoArdelyx dialysis drug approved by FDA after appeal
bizjournals.com - October 17 at 8:21 PM
msn.com logoArdelyx wins long battle for FDA approval of kidney-disease treatment
msn.com - October 17 at 8:21 PM
finance.yahoo.com logoArdelyx Announces Amendment of Debt Financing Agreement with SLR Capital Partners to Provide $50 Million of Additional Committed Capital
finance.yahoo.com - October 17 at 8:21 PM
marketbeat.com logo
marketbeat.com - October 17 at 5:10 PM
markets.businessinsider.com logoHigh Probability of Approval for Ardelyx’s Xphozah: A Positive Outlook on Market Capture and Investment Returns
markets.businessinsider.com - October 13 at 10:39 AM
finance.yahoo.com logoArdelyx, Inc.'s (NASDAQ:ARDX) institutional investors lost 19% over the past week but have profited from longer-term gains
finance.yahoo.com - October 13 at 10:39 AM
finance.yahoo.com logoArdelyx to Present Data Updates for XPHOZAH (tenapanor) for Hyperphosphatemia at Kidney Week 2023 November 1-5 in Philadelphia, PA
finance.yahoo.com - October 13 at 10:39 AM
benzinga.com logoShould You Add Ardelyx Inc (ARDX) Stock to Your Portfolio Monday?
benzinga.com - October 11 at 8:24 PM
finance.yahoo.com logoWhy Shares of Ardelyx Were Down Wednesday
finance.yahoo.com - October 11 at 8:24 PM
msn.com logoArdelyx falls 17% ahead of expected FDA decision on kidney drug
msn.com - October 11 at 3:23 PM
seekingalpha.com logoRising Sun Over Ardelyx: A Tenapanor Tale (Rating Upgrade)
seekingalpha.com - October 9 at 8:55 AM
finance.yahoo.com logoArdelyx Shares Preliminary Data on Use of IBSRELA® (tenapanor) in Pediatric IBS-C Patients at NASPGHAN 2023
finance.yahoo.com - October 4 at 9:36 AM
Get Ardelyx News Delivered to You Automatically

Sign up to receive the latest news and ratings for ARDX and its competitors with MarketBeat's FREE daily newsletter.



ARDX Media Mentions By Week

ARDX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ARDX
News Sentiment
▼
0.33

0.76
▲
Average
Medical
News Sentiment

ARDX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ARDX Articles
This Week
▼
6

3
▲
ARDX Articles
Average Week

Get Ardelyx News Delivered to You Automatically

Sign up to receive the latest news and ratings for ARDX and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

Related Companies:
Headlines Tools:
This page (NASDAQ:ARDX) was last updated on 12/4/2023 by MarketBeat.com Staff

My Account -